AVIGI
✽ AVIGI Therapeutics · Leiden, NL

Upstream of
Kidney Disease.

AVIGI is developing VL166 — a first-in-class covalent heparanase inhibitor designed to protect the kidney's filter, not just manage the symptoms.

See the science →Our program
Approach
First-in-class, covalent heparanase inhibition
Lead program
Diabetic & rare kidney disease
Stage
Preclinical proof of concept
✽ Why heparanase

One enzyme, upstream of the damage.

Heparanase is the only human enzyme that cuts heparan sulfate — the carbohydrate scaffolding of the glomerular filtration barrier. In kidney disease its activity tears that barrier down, driving the inflammation and fibrosis that scar the kidney and leak protein.

VL166 shuts heparanase down permanently, at the source. We believe a durable, upstream brake can protect kidney structure and slow the progression toward end-stage renal disease.

✽ The technology

Watch VL166 lock onto heparanase — atom by atom.

An interactive 3D walkthrough of the covalent mechanism, built from the 1.52 Å crystal structure (PDB 7PR7).